What is Cowden syndrome?
Cowden syndrome (CS) is part of the PTEN hamartoma tumor syndrome. Hamartomas are benign, meaning noncancerous, tumor-like growths. Other clinical syndromes that are part of the PTEN hamartoma tumor syndrome are Bannayan-Riley-Ruvalcaba syndrome (BRR; diagnosed in children), Proteus syndrome, and Proteus-like syndrome. CS is characterized by a high risk of both benign and cancerous tumors of the breast, thyroid, endometrium (uterus), colorectal, kidney, and skin (melanoma).
Other key features of CS are skin changes, such as trichilemmomas (skin tags) and papillomatous papules, and macrocephaly, meaning larger than average head size.
How is CS diagnosed?
The diagnostic criteria for CS are complex and frequently reviewed by geneticists, who are health professionals with specialized training in medical genetics, as new information becomes available. Sometimes CS is difficult to diagnosis. That’s why teams of hereditary cancer risk specialists including oncologists, who are cancer doctors, geneticists, genetic counselors, and nurses certified in hereditary cancer have worked together to create diagnostic categories, termed major and minor criteria, summarized in the National Comprehensive Cancer Network (NCCN) guidelines.
Below are the current major and minor criteria as well as the testing criteria for CS:
Follicular thyroid cancer
Multiple gastrointestinal hamartomas or ganglioneuromas
Macular pigmentation of glans penis, meaning a discolored area on the skin
One biopsy-proven trichilemmoma
Multiple palmoplantar keratosis, meaning abnormal thickening of the hands and feet
Multifocal or extensive oral mucosal papillomatosis
Multiple cutaneous facial papules that are often verrucous, meaning wartlike projections
Esophageal glycogenic acanthosis
Papillary or follicular variant of papillary thyroid cancer
Thyroid structural lesions, such as adenoma, nodule(s), goiter
Renal cell (kidney) carcinoma
Vascular anomalies, including multiple intracranial developmental venous anomalies
Lipomas, meaning benign soft tissue tumor
Single gastrointestinal hamartoma or ganglioneuroma
Cowden Syndrome PTEN Gene Testing Criteria
People with a personal history of:
A family with a known PTEN gene mutation
Meeting clinical diagnostic criteria for CS
Bannayan-Riley-Ruvalcaba syndrome (BRR)
Adult Lhermitte-Duclos disease (cerebellar tumors)
Autism spectrum disorder and macrocephaly
Two or more biopsy-proben trichilemmomas
Two or more major criteria (one must be macrocephaly)
Source: Eng C. Will the real Cowden syndrome please stand up: revised diagnostic criteria. Med Genet 2000;37:828-830.
CS is suspected if a person has either three major criteria without macrocephaly, one major and three minor criteria, four minor criteria, or a relative with a clinical diagnosis of CS or BRR.
Research is ongoing to better understand CS. Approximately 80% of the people who meet the current clinical diagnosis of CS have a mutation in the PTEN gene. A blood test can determine if someone has a mutation in the PTEN gene. If a person has a mutation in the PTEN gene, he or she has CS.
How is CS inherited?
Normally, every cell has 2 copies of each gene: 1 inherited from the mother and 1 inherited from the father. CS follows an autosomal dominant inheritance pattern in which a mutation in only 1 copy of the gene can cause the Cowden syndrome. This means that a parent with a gene mutation may pass along a copy of their normal gene or a copy of the gene with the mutation. It takes only 1 copy of the gene with the mutation to have the disease. Therefore, a parent with a mutation in the PTEN gene has a 50% chance of passing the mutation to their child with each pregnancy. A brother, sister, or parent of a person who has a mutation also has a 50% chance of having inherited the same gene mutation. Learn more about genetics.
Options exist for couples interested in having a child when they know that one of them carries a gene mutation that increases the risk for this hereditary cancer syndrome. Preimplantation genetic diagnosis (PGD) is a medical procedure done in conjunction with in-vitro fertilization (IVF). It allows people who carry a specific known genetic mutation to have children who do not carry the mutation. A woman’s eggs are removed and fertilized in a laboratory. When the embryos reach a certain size, one cell is removed and is tested for the hereditary condition in question. The parents can then choose to transfer embryos that do not have the mutation. PGD has been in use for over two decades, and has been used for several hereditary cancer predisposition syndromes. However, this is a complex procedure with financial, physical, and emotional factors to consider before starting. For more information, talk with an assisted reproduction specialist at a fertility clinic.
How common is CS?
CS is thought to be rare, although it is probably under-diagnosed. It is estimated that CS affects about one in every 200,000 individuals.
As testing for hereditary cancer expands to include multi-gene panels, the classical definition of syndromes such as CS may change. Some individuals may have a mutation in the PTEN gene but do not meet any of the criteria listed above for CS. It is not known if these people will have the same risks for developing cancer.
What are the estimated cancer risks associated with CS?
The greatest cancer risk for a woman with CS is breast cancer. The lifetime risk for a woman with CS to develop breast cancer is estimated to be 85%. Breast cancer may develop earlier in women with CS than the general population. There is also an increased risk for a second breast cancer in the opposite breast and some increased risk of breast cancer in men with CS, but the specific risk is not known.
The risk of thyroid cancer in men and women with CS is estimated to be 35%. Thyroid cancer in CS is most commonly the follicular type but may also be the papillary type.
The risk to develop kidney cancer is 33%, and it is one of the highest cancer risks for those with a PTEN gene mutation.
The risk of endometrial cancer in women with CS is 28%.
The risk for colorectal cancer is 9% and often occurs at a younger age than compared to the general population.
The risk for melanoma is 6%. It is important to be aware of this risk because prevention can begin in childhood by using sunscreen and protective clothing to reduce the number of blistering burns before age 20. Melanoma is a cancer that is influenced by multiple factors including skin color, and eye and hair color, as well as sun exposure and in some cases, inherited gene mutations. If a person tests negative for a PTEN gene mutation that has previously been identified in their family, they may still have risk factors that increase their risk of melanoma.
Many other types of cancer have been seen in people with CS. It is not yet known if the risk of these cancers is increased in people with CS. The list reported includes liver cancer, pancreatic cancer, ovarian cancer, bladder cancer, basal cell and squamous cell skin cancers, Merkel cell skin cancer, brain cancer, liposarcoma, and non-small cell lung cancer.
What are the screening options for CS?
It is important to discuss with your doctor the following screening options, as each person is different.
At the time of diagnosis:
People with CS of all ages: an annual thyroid ultrasound scan and an annual skin exam.
Starting at age 30:
Women with CS: an annual mammogram; an annual breast MRI based on the 2015 guidelines of the National Comprehensive Cancer Network (NCCN); and an annual endometrial biopsy or transvaginal ultrasound (or from 5 years before age of earliest uterine cancer in the family.)
Starting at age 40:
Women with CS: The preventive removal of the breasts before cancer develops through a surgery called a prophylactic mastectomy may be considered. In addition, there can also be the preventive removal of the woman’s uterus, called a prophylactic hysterectomy.
Source: Min-Han Tan, Jessica L. Mester, Joanne Ngeow, et al. “Lifetime Cancer Risks in Individuals with Germline PTEN Mutations” Clin Cancer Res. 2012 January 15; 18(2): 400–407.; and National Comprehensive Cancer Network (http://www.nccn.org).
Surveillance may begin 5 to 10 years earlier than the youngest person diagnosed with a specific cancer in the family, but should begin no later than the ages noted above. The frequency of scheduled colonoscopies may increase based on how many polyps are found.
Screening options may change over time as new technologies are developed and more is learned about CS. It is important to talk with your doctor about appropriate screening tests.
Learn more about what to expect when having common tests, procedures, and scans.
Questions to ask the doctor
If you are concerned about your risk of cancer, talk with your doctor. Consider asking the following questions:
What is my risk of developing cancer?
Where can I be referred to for a hereditary cancer risk assessment?
What can I do to reduce my risk of cancer?
What are my options for cancer screening?
If you are concerned about your family history and think your family may have CS, consider asking the following questions:
Does my family history increase my risk of cancer?
Could my family have CS?
Will you refer me to a genetic counselor for a cancer risk assessment?
Should I meet with a genetic counselor?
Facing Our Risk of Cancer Empowered (FORCE)
Information for women who are at a high risk of developing ovarian cancer or breast cancer.
National Comprehensive Cancer Network (NCCN)
National Cancer Institute
American Cancer Society
To find a genetic counselor in your area, ask your doctor or visit these websites:
National Society of Genetic Counselors
National Cancer Institute: Cancer Genetics Services Directory